BUPIVACAINE INJECTION BP 5 MG
BUPIVACAINE HYDROCHLORIDE : 5 MG · DIN 02443694 · STERIMAX INC
Health Canada status: MARKETED
What is BUPIVACAINE INJECTION BP?
BUPIVACAINE INJECTION BP 5 MG contains BUPIVACAINE HYDROCHLORIDE : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02443694, held by STERIMAX INC, supplied as SOLUTION for EPIDURAL ; BLOCK/INFILTRATION administration. Health Canada currently lists it as marketed, status dated 20-May-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BUPIVACAINE INJECTION BP used for?
Production of local or regional anaesthesia or analgesia for local infiltration, peripheral nerve blocks, and epidural blocks (surgery, postoperative, or labour pain relief).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02443694 |
|---|---|
| Brand name | BUPIVACAINE INJECTION BP |
| Generic / active ingredient | BUPIVACAINE HYDROCHLORIDE : 5 MG |
| Manufacturer | STERIMAX INC |
| Strength | 5 MG |
| Dosage form | SOLUTION |
| Route of administration | EPIDURAL ; BLOCK/INFILTRATION |
| Schedule | Ethical |
| ATC code | N01BB01 BUPIVACAINE |
| AHFS class | 72:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 20-May-2016 |
| Original market date | 2016-05-20 00:00:00 |
How is it administered?
Varies by procedure. Adults: Max 400 mg/24h. Inject slowly with frequent aspiration. Children >2 years: up to 2 mg/kg. Not for spinal use. Not for intra-articular infusion.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Section 11 mentioned but content not fully visible), typically 15-30°C for similar products.
How is it supplied?
0.25% (2.5 mg/mL) and 0.5% (5 mg/mL) available in 10 mL and 20 mL vials.
Contraindications
Hypersensitivity to bupivacaine or amide-type local anaesthetics; intravenous regional anaesthesia (Bier block); obstetric paracervical block anaesthesia.
Warnings and precautions
Risk of cardiac arrest/death; irreversible chondrolysis reported with unapproved intra-articular infusion; risk of systemic toxicity if injected intravascularly.
Is BUPIVACAINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by OMEGA LABORATORIES LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N01BB01 BUPIVACAINE. 10 of 42 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP | 7.5 MG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02512424 |
| BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP | 7.5 MG | SOLUTION | FORMATIVE PHARMA INC. | MARKETED | DIN 02536714 |
| BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP | 7.5 MG | SOLUTION | STERIMAX INC | MARKETED | DIN 02460645 |
| BUPIVACAINE HYDROCHLORIDE INJECTION, USP | 7.5 MG | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02488930 |
| BUPIVACAINE INJECTION BP | 2.5 MG | SOLUTION | STERIMAX INC | MARKETED | DIN 02443686 |
| MARCAINE | 150 MG / 20 ML | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02241917 |
| MARCAINE | 250 MG / 50 ML | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02305909 |
| SENSORCAINE | 2.5 MG | SOLUTION | ASPEN PHARMACARE CANADA INC. | MARKETED | DIN 01976141 |
| SENSORCAINE | 5 MG | SOLUTION | ASPEN PHARMACARE CANADA INC. | MARKETED | DIN 01976168 |
| BUPIVACAINE HEAVY INJECTION BP | 15 MG / 2 ML | SOLUTION | AURO PHARMA INC | APPROVED | DIN 02470616 |
Who else supplies BUPIVACAINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BUPIVACAINE appears in 19 registered pack listings across 5 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.